New enzyme replacement therapies launched

Patients with two rare inherited metabolic conditions can now benefit from treatment with specific enzyme replacement therapies.

Kanuma (sebelipase alfa) is licensed for use in patients with lysosomal acid lipase deficiency, a condition causing chronic build-up of cholesteryl esters and triglycerides in the liver, blood vessel walls and other tissues, leading to multi-organ damage and premature death. 

Further information
View Kanuma drug record
View Strensiq drug record
Manufacturer: Alexion

Strensiq (asfotase alfa) is indicated for the treatment of paediatric-onset hypophosphatasia, a disorder caused by low levels of alkaline phosphatase and characterised by defective bone mineralisation that can lead to bone deformity and destruction, muscle weakness, seizures, respiratory failure and premature death. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

'Innovative' heart failure treatment recommended by NICE

'Innovative' heart failure treatment recommended by NICE

Dapagliflozin (Forxiga), the first SGLT2 inhibitor...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregabalin linked to severe respiratory depression in absence of opioids

Pregabalin linked to severe respiratory depression in absence of opioids

The MHRA advises prescribers to consider adjustment...